Trial Profile
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Elosulfase alfa (Primary)
- Indications Mucopolysaccharidosis IV
- Focus Adverse reactions; Therapeutic Use
- Acronyms MARS
- Sponsors BioMarin Pharmaceutical
- 04 Mar 2024 Status changed from active, no longer recruiting to completed.
- 15 Jun 2022 Status changed from recruiting to active, no longer recruiting.
- 22 Nov 2014 New trial record